Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy
Risk factors and course of steroid diabetes were investigated in 145 renal-transplant recipients who were given a high-dose steroid regimen. Persistent steroid diabetes developed in 25% of the patients and transient diabetes in another 22%. When antidiabetic therapy was required, insulin had to be given in 50%. The incidence of steroid diabetes correlated with steroid dose, age, body weight, and diabetes heredity but not with abnormal glucose tolerance or with another complication of steroid therapy, posterior-pole lenticular cataract. There was no association with HLA-A and B antigens. Thus, steroid diabetes is a frequent complication of high-dose corticosteroid therapy and is similar to type II diabetes. However, it often requires insulin therapy.
Effect of cyclosporin A, azathioprine, and prednisolone on carbohydrate metabolism of rat hepatocytes
Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients
Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation
Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?
beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003
Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy
Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs
New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression
Increased body mass index but not common vitamin D receptor, peroxisome proliferator-activated receptor γ, or cytokine polymorphisms confers predisposition to posttransplant diabetes
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?
Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation
Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion
Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression
Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo
Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation
Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?
Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels
American Diabetes Association Journals
Discover the latest diabetes research published by the journals from the American Diabetes Association.